High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial. (linkinghub.elsevier.com)

Authors: Yan H … Zhang Y Journal: Cell Reports Medicine Published: 2026-06-30 DOI: https://doi.org/10.1016/j.xcrm.2026.102904